Ladenburg Thalmann Financial Services Inc. decreased its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 10.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,516 shares of the biopharmaceutical company’s stock after selling 414 shares during the period. Ladenburg Thalmann Financial Services Inc.’s holdings in Alexion Pharmaceuticals were worth $422,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of ALXN. Amundi Pioneer Asset Management Inc. boosted its holdings in Alexion Pharmaceuticals by 1,786.3% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 1,454,498 shares of the biopharmaceutical company’s stock valued at $173,944,000 after acquiring an additional 1,377,388 shares during the last quarter. Investec Asset Management LTD acquired a new position in Alexion Pharmaceuticals in the fourth quarter valued at about $84,096,000. Alkeon Capital Management LLC acquired a new position in Alexion Pharmaceuticals in the third quarter valued at about $70,145,000. TIAA CREF Investment Management LLC lifted its stake in Alexion Pharmaceuticals by 12.1% in the fourth quarter. TIAA CREF Investment Management LLC now owns 3,836,919 shares of the biopharmaceutical company’s stock valued at $458,857,000 after buying an additional 414,969 shares during the period. Finally, Clearbridge Investments LLC lifted its stake in Alexion Pharmaceuticals by 9.5% in the fourth quarter. Clearbridge Investments LLC now owns 3,541,871 shares of the biopharmaceutical company’s stock valued at $423,572,000 after buying an additional 307,117 shares during the period. Institutional investors and hedge funds own 95.36% of the company’s stock.
In related news, EVP Julie O’neill sold 1,625 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $119.83, for a total value of $194,723.75. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Paul J. Clancy sold 6,079 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $116.31, for a total value of $707,048.49. Following the completion of the sale, the chief financial officer now directly owns 95,093 shares in the company, valued at approximately $11,060,266.83. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 28,700 shares of company stock worth $3,345,708. 4.35% of the stock is currently owned by insiders.
Several research firms have weighed in on ALXN. Evercore ISI raised Alexion Pharmaceuticals from an “in-line” rating to an “outperform” rating in a research note on Monday, February 5th. Citigroup cut their target price on Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating on the stock in a research note on Friday, February 9th. Nomura increased their target price on Alexion Pharmaceuticals from $148.00 to $156.00 and gave the company a “buy” rating in a research note on Thursday, March 15th. BMO Capital Markets increased their target price on Alexion Pharmaceuticals from $177.00 to $180.00 and gave the company an “outperform” rating in a research note on Friday, February 9th. Finally, Leerink Swann cut their target price on Alexion Pharmaceuticals from $166.00 to $153.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and twenty have issued a buy rating to the company. Alexion Pharmaceuticals currently has an average rating of “Buy” and an average target price of $155.55.
NASDAQ ALXN opened at $109.24 on Friday. The stock has a market cap of $24,305.99, a PE ratio of 21.17, a price-to-earnings-growth ratio of 1.01 and a beta of 1.13. The company has a current ratio of 3.10, a quick ratio of 2.62 and a debt-to-equity ratio of 0.34. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 EPS for the quarter, topping the Zacks’ consensus estimate of $1.09 by $0.39. The company had revenue of $909.70 million for the quarter, compared to analyst estimates of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. Alexion Pharmaceuticals’s revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.26 earnings per share. research analysts anticipate that Alexion Pharmaceuticals, Inc. will post 6.12 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/08/ladenburg-thalmann-financial-services-inc-sells-414-shares-of-alexion-pharmaceuticals-inc-alxn.html.
Alexion Pharmaceuticals Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.